Novo Nordisk reported strong fourth-quarter earnings, exceeding analysts' expectations with a 37% rise in operating profit. However, the company anticipates slower growth in 2025 due to increased competition, particularly from Eli Lilly. The sales of its weight-loss drug Wegovy grew significantly, but annual growth rates have slowed. Investors are concerned about the future as competition intensifies and R&D costs rise. Teljes cikk (Euronews.com)